PARP Inhibitors Could Enhance Immunotherapy Response in Mesothelioma

mesothelioma immunotherapy response

A new study suggests that drugs known as PARP inhibitors may enhance immunotherapy response in mesothelioma patients. According to a report published in the Journal of Clinical Investigations, PARP inhibitors worked especially well in cancers with mutations in their DNA repair genes. Some malignant mesothelioma patients have mutated DNA repair genes. In these patients, a PARP inhibitor may modify immunotherapy response, making drugs like Keytruda work better. How PARP Impacts Immunotherapy Response PARP stands for poly (ADP-ribose) polymerase. It represents a family of proteins involved in a number of cellular processes, including DNA repair. PARP is also involved in apoptosis, or programmed cell death. Olaparib (Lynparza) is an example of a PARP inhibitor. PARP inhibitors attack tumors that already have … Continue reading PARP Inhibitors Could Enhance Immunotherapy Response in Mesothelioma »

Mesothelioma Research Demonstrates Power of Intrapleural Immunotherapy

X-ray showing location of intrapleural immunotherapy

New metadata suggests that intrapleural immunotherapy is a powerful, targeted way to treat malignant pleural mesothelioma.   Pleural mesothelioma is a deadly cancer of the lining around the lungs. It is caused by asbestos exposure and is notoriously difficult to treat. Now, a new study suggests that delivering immunotherapy treatments directly into the pleural space where mesothelioma tumors form may help these drugs work even better. What is Intrapleural Immunotherapy? Immunotherapy treatments harness the immune system to help fight cancer. Immunotherapy works alone or in combination with other treatments like chemotherapy or surgery. Many researchers and doctors believe that immunotherapy is the future of mesothelioma treatment. Intrapleural immunotherapy is a more targeted way to deliver these cancer-fighting messengers. It does … Continue reading Mesothelioma Research Demonstrates Power of Intrapleural Immunotherapy »

New Mesothelioma Immunotherapy Treatment Reduces Tregs with Immunotoxin

mesothelioma immunotherapy response

There is a new mesothelioma immunotherapy treatment in the works. This one is based on reducing the number of Tregs or regulatory T-cells around a mesothelioma tumor. Tregs are an important part of maintaining balance in the immune system. They help protect people against autoimmune diseases like MS and lupus. But in people with malignant mesothelioma and other types of cancer, too many Tregs can be a problem. Tregs respond to distress signals sent out by a tumor. They surround the tumor and protect it against attack from the immune system. The goal of mesothelioma immunotherapy treatment is to reactivate the immune system to fight the cancer. Developing a Mesothelioma Immunotherapy Treatment Molecular biologists at the National Cancer Institute and … Continue reading New Mesothelioma Immunotherapy Treatment Reduces Tregs with Immunotoxin »

New Mesothelioma Drug Trial Begins

mesothelioma drug trial

A new mesothelioma drug trial is now underway. The trial will test a brand new type of immunotherapy medication called CA-170. CA-170 is designed to block an immune system suppressor called VISTA. It is the only VISTA-blocking medication currently in clinical trial. “CA-170 has demonstrated favorable safety and tolerability as well as preliminary anti-tumor activity in patients across multiple tumor types,” the company said in a statement. Mesothelioma Drug Trial Focuses on VISTA Malignant mesothelioma is highly resistant to standard cancer treatments. Many top researchers believe that immunotherapy drugs offer the best promise for curing mesothelioma. That is because cancers like malignant mesothelioma survive in part by evading detection by the immune system. They do this in a variety ways … Continue reading New Mesothelioma Drug Trial Begins »

BAP1 Can Distinguish Mesothelioma from Other Conditions

Scientist looking at mesothelioma cells

German scientists say a protein could help doctors distinguish mesothelioma from other conditions. Malignant mesothelioma is a cancer that grows on the membranes around organs. These membranes are called mesothelial membranes. But other conditions can also grow on mesothelial membranes. One of those conditions is adenomatoid tumors. Adenomatoid tumors are benign but, even under the microscope, their cells can look a lot like malignant mesothelioma. Now, a group of pathologists in Germany say the BAP1 protein can tell these two conditions apart. If doctors can distinguish mesothelioma from other conditions early enough, mesothelioma patients may have better outcomes. BAP1 Loss and Mesothelioma BAP1 is a protein encoded by the BAP1 gene. BAP1 is one of the proteins that helps keep … Continue reading BAP1 Can Distinguish Mesothelioma from Other Conditions »

Chemotherapy for Mesothelioma May Work Better with TroVax

vaccine added to chemotherapy for mesothelioma

UK researchers say a cancer vaccine called Trovax has the potential to boost the power of chemotherapy for mesothelioma. Chemotherapy is the main treatment for malignant pleural mesothelioma. Mesothelioma is a cancer of the lung lining caused by asbestos exposure. It is very hard to treat. Even people who have chemotherapy for mesothelioma do not usually live more than two years after diagnosis. Mesothelioma researchers are always looking for ways to improve chemotherapy for mesothelioma. It is often combined with other treatments like surgery, radiation or immunotherapy. Now, scientists think adding TroVax to mesothelioma chemotherapy may be another good option. What is the TroVax Cancer Vaccine? The TroVax cancer vaccine is made by UK-based Oxford BioMedica. It contains an altered … Continue reading Chemotherapy for Mesothelioma May Work Better with TroVax »

Survival After Mesothelioma Surgery Could Rise with Immunotherapy Spray

improving survival after mesothelioma surgery

A spray-on immune booster may one day improve survival after mesothelioma surgery. UCLA scientists tested the biodegradable spray gel in mice with advanced melanoma. They found that it stopped cancer recurrence after surgery in about half of the lab animals tested. “Around 90 percent of people with cancerous tumors end up dying because of tumor recurrence or metastasis,” says lead investigator Zhen Gu. “Being able to develop something that helps lower this risk for this to occur and has low toxicity is especially gratifying.” Gu is a professor of bioengineering and a member of the UCLA Jonsson Comprehensive Cancer Center where the spray was developed. Survival After Mesothelioma Surgery Survival after mesothelioma surgery or any other kind of cancer operation … Continue reading Survival After Mesothelioma Surgery Could Rise with Immunotherapy Spray »

Immunotherapy for Peritoneal Mesothelioma: New Drug Trial Begin

immunotherapy for peritoneal mesothelioma

Researchers in Maryland and Missouri have started human testing of a new type of immunotherapy for peritoneal mesothelioma. If the human trial of this new CAR T-cell therapy goes as well as the laboratory tests, this could be good news for many people with asbestos cancer. CAR stands for chimeric antigen receptor. CAR T-cell therapy works by “reprogramming” a patient’s immune system to fight cancer cells. Tests show this therapy can work well for blood-based cancers like leukemia. But the results have not been as good for solid tumors like peritoneal mesothelioma. MaxCyte is the American company than makes the new drug. They are hoping that their approach to immunotherapy for peritoneal mesothelioma will be better. Preparing CAR T-cell Therapy … Continue reading Immunotherapy for Peritoneal Mesothelioma: New Drug Trial Begin »

Radiation May Help Mesothelioma Immunotherapy Treatment Work Better

mesothelioma radiation treatment

Hypofractionated radiation for mesothelioma could change how doctors treat this rare cancer.  Researchers in Toronto, Canada have been testing hypofractionated radiation in mesothelioma surgery patients. They have used it to shrink tumors before lung-removing EPP surgery. Hypofractionated radiation is faster than than standard radiation. It may also cause fewer side effects. Now, doctors want to know what else this type of radiation might be good for. They plan to test how well hypofractionated radiation works with less radical mesothelioma surgery. There is also evidence that hypofractionated radiation may strengthen mesothelioma immunotherapy treatment. Radiation Before Mesothelioma Surgery Doctors at the Princess Margaret Cancer Center in Toronto ran a clinical trial called SMART. SMART stands for Surgery for Mesothelioma After Radiation Therapy. … Continue reading Radiation May Help Mesothelioma Immunotherapy Treatment Work Better »

Ofev Fails to Boost Mesothelioma Survival in New Study

In the quest to develop new, more effective first-line treatments for malignant pleural mesothelioma, it now looks like Ofev (nintedanib) is out of the running. Phase III results of the LUME-Meso mesothelioma trial are in and they contain some disappointing news for mesothelioma patients and for the drug’s developer, Boehringer Ingelheim. The news is especially disappointing since the results of the Phase II portion of the trial, released last year, looked promising. At that time, researchers reported a survival gain of more than 5 months among the Ofev-treated mesothelioma patients and progression-free survival of four months. But further research did not support those results, as investigators announced to the world’s lung cancer experts at the IASLC 19th World Lung Cancer … Continue reading Ofev Fails to Boost Mesothelioma Survival in New Study »

Get your free copy of
“Surviving Mesothelioma” Today!